Shanghai Pharmaceuticals Holding Co Ltd
XBER:S1R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
XBER:S1R
|
CN |
|
V
|
Valeo SE
SWB:VSA2
|
FR |
|
V
|
Verbund AG
XHAM:OEWA
|
AT |
|
I
|
ImmunoGen Inc
DUS:IMU
|
US |
|
B
|
Borgwarner Inc
F:BGW
|
US |
|
L&T Finance Holdings Ltd
NSE:L&TFH
|
IN |
|
N
|
Navamedic ASA
F:N1A
|
NO |
Wall St Price Targets
S1R Price Targets Summary
Shanghai Pharmaceuticals Holding Co Ltd
According to Wall Street analysts, the average 1-year price target for S1R is 1.57 EUR with a low forecast of 0.95 EUR and a high forecast of 2.04 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S1R's stock price target?
Price Target
1.57
EUR
According to Wall Street analysts, the average 1-year price target for S1R is 1.57 EUR with a low forecast of 0.95 EUR and a high forecast of 2.04 EUR.
What is the Revenue forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 2 years is 10%.
What is the Operating Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
12%
Over the last 14 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 2 years is 12%.
What is the Pre-Tax Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 9%. The projected CAGR for the next 2 years is 7%.
What is the Net Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 2 years is 8%.
